Beovu, Novartis’ wet age-related macular edema treatment, has been granted a permanent J-code from CMS, effective Jan. 1, 2020.
Beovu (brolucizumab-dbll) was approved by the FDA in October 2019 and is the first anti-VEGF approved for 3-month dosing intervals following a 3-month loading phase.
J0179 establishes a new level II HCPCS code for “Injection, brolucizumab-dbll, 1 mg,” according to the CMS.gov website.
“We were pleased to receive a permanent J-code for Beovu earlier than anticipated,” Patrick Mooney, vice president and head of Novartis’ U.S.
Uncategorized